Home / Stock ratings / Healthcare Stocks / MDT
Stock rating · Electromedical & Electrotherapeutic Apparatus
Medtronic plc (MDT) Stock Rating & Analysis
As of October 6, 2026, MELANY rates Medtronic plc 66 out of 100 (Favorable). Its highest factor score is catalyst setup at 81, and its lowest are price momentum and macro fit at 50.
MELANY ratingRated 2026-10-06MDT · composite score
About Medtronic plc
Medtronic, among the largest medical-device companies, develops and manufactures therapeutic devices for chronic diseases, including pacemakers, defibrillators, transcatheter heart valves, stents, spinal fixation devices, neurovascular products, advanced energy, ablation laser therapy, and surgical tools. It markets mainly to healthcare institutions and physicians in the US, Western Europe, and Japan, with foreign sales making up roughly 50% of total sales.
Rating as of 2026-10-06 · this is a dated snapshot; the live rating is in the app (Pro, free for 30 days). The price above updates in real time.
Why MDT scores 66/100
MDT's 8 factor scores run from 50 to 81, and 4 of them sit above its composite of 66. Here is how MDT breaks down.
Whether the price looks cheap or expensive against earnings, growth, and peers.
- Forward P/E 13.6x, earnings growth accelerating
Margins, returns on capital, and balance-sheet strength.
- Gross margin 65%
Direction and relative strength of the recent share-price trend.
History of beating or missing estimates, and where estimates are heading.
- Beat EPS estimates 3 of last 4 quarters
What Wall Street price targets and revisions are signalling.
Near-term events that could move the stock.
Upside weighed against volatility and drawdown risk.
How the current rate and market regime suits this kind of company.
How MDT compares
As of October 7, 2026, Medtronic plc is tied for 12th of 20 in Healthcare Stocks, where the average score is 67.
Key risks for MDT
- No specific company-level red flags detected, monitor macro regime changes
Sector and theme context
Medtronic plc sits in the Healthcare sector theme, which MELANY currently rates 37/100 for strength. Theme strength feeds MDT's momentum and catalyst factors above.
MDT trade plan (Pro)
MELANY has a full position plan for Medtronic plc: a smart entry zone, an alert level, position sizing, and quarterly review triggers. It is part of Market Eyes Pro, and the first 30 days are free.
How MELANY rates MDT
MELANY is a rules-based engine that scores every stock from 0 to 100 across eight weighted factors, then re-scores as new price, earnings, and fundamental data arrive. Medtronic plc's 66/100 reflects mature factor weighting for its profile. Position framework managed by score-based check-ins, not a fixed holding period.
Ratings are algorithmic and change with the data. They are research and education, not personalized investment advice.
Frequently asked questions about MDT
Is Medtronic plc (MDT) a buy?
As of 2026-10-06, MELANY rated Medtronic plc Favorable with a composite score of 66/100. That is a dated snapshot, not the live rating, and it is an algorithmic reading built from eight factors rather than personalized investment advice. Review the factor breakdown above and the disclaimer below before making any decision.
What is Medtronic plc's MELANY score?
Medtronic plc (MDT) has a MELANY composite score of 66/100, combining valuation, business quality, price momentum, earnings track record, analyst sentiment, catalyst setup, risk-adjusted profile, macro fit.
How is the MDT stock rating calculated?
MELANY scores MDT from 0 to 100 across eight weighted factors using live market and fundamental data, then refreshes the rating automatically as new data arrives.
Should I buy Medtronic plc stock?
That decision is yours; Market Eyes Live does not give buy or sell advice. What the data says: MELANY rates Medtronic plc (MDT) Favorable with a composite of 66/100 as of 2026-10-06. The factor breakdown above shows what is driving that, which is a better basis for a decision than any one-word verdict.
What is the MDT stock price forecast?
MELANY does not publish price targets or forecasts for MDT. Predicting a future price is exactly the kind of false precision the confidence framework avoids. Instead it scores today's setup, 66/100 across eight factors for Medtronic plc, and re-scores automatically as new price, earnings, and fundamental data arrive.
Is MDT stock overvalued or undervalued?
MELANY's valuation factor currently reads 66/100 for Medtronic plc, where a higher score means the price looks more attractive on that measure. Scores in the 70s and above read as attractively priced, the mid range as roughly fair, and low scores as stretched. The factor breakdown above shows what drives MDT's read.
What price should I buy MDT at?
Rather than chasing the current price, MELANY computes a smart entry zone for MDT: the price area where risk and reward actually favor a new position, plus an alert level and position sizing. The exact levels are part of Market Eyes Pro, which starts with a 30-day free trial.
What are the risks of buying MDT stock?
The top risks MELANY currently flags for Medtronic plc: No specific company-level red flags detected, monitor macro regime changes. The rating on this page already weighs these against the bullish factors; see the risk-adjusted profile score in the breakdown above.
Is Medtronic plc a good long-term investment?
For long-term durability the two factors that matter most are business quality, which MELANY scores 65/100 for Medtronic plc, and earnings track record, at 67/100. The 66/100 composite blends those with six shorter-horizon factors. Durable quality at a fair price is the long-term case to test; this is research, not personalized investment advice.
Will MDT stock go up?
Nobody can promise a stock's direction, and Market Eyes Live does not predict prices. The measurable part: MELANY's price momentum factor reads 50/100 for MDT right now, and the catalyst setup factor tracks whether near-term events could move it. Both re-score automatically as the data changes.
How current is this MDT rating?
The rating on this page is a snapshot of MELANY's read as of 2026-10-06. The price shown updates live, but the score is not recomputed on this page. MELANY re-scores MDT continuously as new price, earnings, and fundamental data arrive, and the current rating is in the app (Pro, free for 30 days).
How this rating works
Market Eyes Live
Every rating graded in public, MDT included
MELANY scores more than 11,000 U.S. stocks and ETFs, PRISM ranks conviction and APEX writes the plan with one entry zone. Free to start on iOS and the web.